How to Find Clinical Advisors for Your Healthtech Startup

Why most founders start this search with the wrong question

If you are searching for how to find clinical advisors for your healthtech startup, you have almost certainly asked the question in the wrong order. The default founder instinct is to chase names: a recognisable consultant from a London teaching hospital, a professor with a long publication list, a former NHS digital lead with a LinkedIn following. That instinct optimises for the wrong thing.

A clinical advisor adds value in one of two ways. They open doors you cannot open yourself, or they sit inside your product process and catch the safety, workflow, and evidence problems you would otherwise ship into pilots. The two are different jobs, and almost every early-stage healthtech founder confuses them.

Before you do any sourcing, write down which of those two outcomes you actually need from your first hire. The rest of this post assumes you have done that.

The four roles people lump together as "clinical advisor"

The phrase "clinical advisor" is doing far too much work in healthtech. In practice there are four distinct roles, and conflating them is the single most common reason advisory boards in early-stage healthtech do nothing useful.

The figurehead. A senior name on your deck and website. Investors recognise them. Hospitals take the call when they reach out. They do not review your product, sit on weekly calls, or read your evidence dossier. This role exists, it is valid, and it should be priced and managed accordingly.

The clinical reviewer. The clinician who reads what you build before it goes to a patient. They flag the missing safety nets, the unrealistic workflow assumptions, the cohort you are quietly excluding. This is the role that prevents your product from failing its first clinical safety case under DCB0129 review.

The evidence partner. The clinician who co-designs and co-authors the evidence you will need for NHS DTAC, payer conversations, or regulatory submission. They expect to be on the publication, not on a retainer alone.

The market opener. The clinician who introduces you to the procurement lead at a Trust, gets you into a CCIO's diary, or lets you trial your product with their team. This is the role that compresses your sales cycle from eighteen months to six.

Most startups buy one person and expect all four jobs. That is the first failure mode.

Where to find them

Once you know which role you are filling, sourcing gets easier. Three channels actually work in the UK healthtech ecosystem, and one channel mostly wastes founder time.

The clinical entrepreneur networks run by NHS England (the Clinical Entrepreneur Programme) and AHSNs are the highest-yield channel. The clinicians who join those programmes have already self-selected for wanting to build, not just advise. They understand product timelines, equity, and the gap between an idea and a regulated medical device.

Specialty society events and conferences are the second channel, and they are underused. The Royal College of Physicians, the BCS Faculty of Clinical Informatics, and condition-specific societies (BSG for gastro, BTS for thoracic, and so on) all run smaller meetings where you can meet clinicians who care about your specific area. A conference dinner conversation closes more advisor hires than three months of LinkedIn outreach.

The third channel is purpose-built marketplaces. Orbion Connect exists for this reason: it lets you specify the role you actually need, the time commitment, and the speciality, and matches you against clinicians who have agreed terms in advance. The advantage over cold outreach is speed, and the advantage over your existing network is that the clinician has already opted into commercial work and declared the relevant conflicts.

The channel that wastes time is mass LinkedIn outreach to senior consultants. The response rate is poor, the people who do respond are often the wrong fit, and the signal you send by cold-messaging at scale damages your founder credibility in a small ecosystem.

What to pay them

Compensation for clinical advisors is where startups either overpay one figurehead or underpay a real working partner. The market data is clearer than founders assume.

Equity-only advisory grants typically sit between 0.15% and 1% of the company depending on stage and time commitment, vesting over two years, with an explicit termination clause if either side wants out per Silicon Valley Bank benchmarks. Cash retainers for working clinical advisors in the UK usually run between £400 and £1,000 per day for senior consultants, with a clear monthly cap. A market opener role is often best done on a referral fee or success-based structure tied to a specific Trust introduction or pilot.

Pay structure matters more than headline number. If you grant 0.5% with a one-year cliff to someone who has been on your deck for six weeks and then ghosts you, you have a cap table problem. Build a 90-day trial period into every clinical advisor agreement, with a small equity vest on completion and the larger grant gated on a clear deliverable.

Two compliance points worth getting right early. Aggregate compensation to physician advisors should be at fair market value and commercially reasonable, particularly if your product touches procurement decisions per Fenwick's guidance on physician advisor compensation. And UK clinicians have GMC obligations to declare commercial interests where they could influence clinical decisions, so your contract should require they manage those declarations on their side.

A startup example, an NHS example, and a failure

A seed-stage diagnostic startup we worked with needed a clinical reviewer, not a figurehead. They paid a Band 8 clinical scientist £800/day for two days a month on a rolling contract, gave a small 0.1% advisory grant after six months, and got a working partner who caught three workflow assumptions that would have failed their first NHS pilot. Total spend in the first year was under £25,000.

Inside the NHS, the equivalent function looks very different. A trust-employed Clinical Safety Officer running DCB0129 reviews on an internal digital service has the same job (catching the safety case problems before they reach a patient) but does it as part of an established quality role. If you are a startup, you are buying back a slice of that institutional capability before you can hire it in-house. The closer your advisor's daily work resembles a CSO's daily work, the more useful they will be in the first eighteen months.

The failure pattern to avoid: hiring a single famous consultant on 1% equity with no defined deliverables, no monthly cadence, and no termination trigger. The advisor is too busy to do the work, the founders are too polite to chase, and a year later the equity has vested and the company has nothing to show for it. The fix is structural, not personal. Write the role, write the deliverables, write the exit ramp.

How to know you've picked the right one

Three signals tell you within ninety days whether your clinical advisor is the right hire.

The first is whether they push back. A good clinical advisor will challenge a design decision in your first product review and keep doing it. If every call ends in agreement, you have hired a figurehead by accident.

The second is whether they bring you problems you had not seen. Inside the first quarter, the right advisor surfaces at least one risk you were not tracking: a workflow assumption, a patient cohort gap, a regulatory classification question. If they only respond to your agenda, the relationship is too shallow.

The third is whether they introduce you to other clinicians. A working clinical advisor naturally pulls in their network when relevant. Silence here is a signal that they are protecting their reputation against your unproven product, which is also useful information about how strong the product needs to get before it earns endorsement.

What to do this week

Spend one hour mapping which of the four roles your company actually needs in the next six months. Be honest about whether you need a market opener, a reviewer, an evidence partner, or a figurehead. You can hire more than one over time, and you should, but you cannot hire one person who plays all four roles competently in a young company.

Then write a one-page role brief: the deliverables you expect, the time commitment, the cash and equity envelope, and the termination terms. Send that brief to three sourcing channels in parallel: your existing clinical network, one specialty society or NHS Clinical Entrepreneur contact, and Orbion Connect for a faster match against pre-cleared clinicians.

By the end of next week you should have three first conversations booked. By the end of the month you should have a 90-day trial agreement signed with one of them. That is the cadence that turns a vague search for healthtech clinical advisors into a working relationship that actually moves the company forward.

If you want to see how other healthtech teams have structured their first clinical advisor hires, our case studies walk through the contracts, the role briefs, and the outcomes in more detail.